PHAR
Cairo – Mubasher: The Egyptian International Pharmaceutical Industries (EIPICO) has started manufacturing the coronavirus (COVID-19) treatment medicine (Epifluver – Favipiravir 200 mg) after obtaining the Egyptian Drug Authority’s (EDA) approval.
The medicine has been used in Russia and China in treating COVID-19 patients, the company said in a statement to the Egyptian Exchange (EGX) on Tuesday.
EIPICO will also begin manufacturing the antiviral drug Remdesivir in the near future.
It is worth mentioning that during the first quarter of 2020, EIPICO reported net profits of EGP 189.1 million, down from EGP 218.31 million in the corresponding period a year earlier.